SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
TG Therapeutics Recaps Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The 3rd Congress Of The European Academy Of Neurology
June 26, 2017
 · 
4 min read
Drug Development
TG Therapeutics Recaps Data From Triple Combination Therapy Trials At The 22nd European Hematology Association Annual Congress
June 26, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma
June 16, 2017
 · 
11 min read
Drug Development
TG Therapeutics Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma
June 14, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO
June 5, 2017
 · 
8 min read
Drug Development
TG Therapeutics Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial
May 23, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The ASCO
May 18, 2017
 · 
4 min read
Drug Development
TG Therapeutics: Significant Near-Term Catalysts For 2017
May 16, 2017
 · 
1 min read
Business
TG Therapeutics Provides Business Update And Reports First Quarter 2017 Financial Results
May 5, 2017
 · 
1 min read
Drug Development
TG Therapeutics Announces Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The American Academy of Neurology
April 28, 2017
 · 
6 min read
Drug Development
TG Therapeutics Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study
March 6, 2017
 · 
10 min read
Bay Area's Depomed Craters as New CEO, Directors are Named in Deal with Activist Investor
Drug Development
TG Therapeutics, Inc. Stock Plunges as Company Modifies Phase III Cancer Trial Protocols
October 14, 2016
 · 
2 min read
Drug Development
TG Therapeutics, Inc. Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab)
May 3, 2016
 · 
6 min read
Drug Development
TG Therapeutics, Inc. Announces Data Presentations For TGR-1202 And TG-1101 In Combination With Ibrutinib At The 57th American Society of Hematology Annual Meeting
December 7, 2015
 · 
8 min read
Drug Development
TG Therapeutics, Inc. Announces Data Presentations At The 57th American Society of Hematology Annual Meeting From Ongoing Clinical Studies In Patients With Non-Hodgkins Lymphoma (NHL) And Chronic Lymphocytic Leukemia (CLL)
December 7, 2015
 · 
8 min read
TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 57th American Society of Hematology Annual Meeting
December 4, 2015
 · 
3 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS